Detalhe da pesquisa
1.
Further phenotype description, genotype characterization in patients with de novo interstitial deletion on 2p23.2-24.1.
Am J Med Genet A
; 164A(7): 1789-94, 2014 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-24700699
2.
Influence of perfusate temperature on nasal potential difference.
Eur Respir J
; 42(2): 389-93, 2013 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-23100510
3.
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
Thorax
; 67(1): 12-8, 2012 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-21825083
4.
Exophiala (Wangiella) dermatitidis and cystic fibrosis - Prevalence and risk factors.
Med Mycol
; 48 Suppl 1: S4-9, 2010 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-21067329
5.
Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice.
Am J Respir Crit Care Med
; 179(11): 1022-8, 2009 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-19299496
6.
Transient elastography in patients with cystic fibrosis.
Pediatr Radiol
; 40(7): 1231-5, 2010 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-20135110
7.
A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference.
J Cyst Fibros
; 11(3): 231-6, 2012 May.
Artigo
Inglês
| MEDLINE | ID: mdl-22281182
8.
Impact of polymorphism of Multidrug Resistance-associated Protein 1 (ABCC1) gene on the severity of cystic fibrosis.
J Cyst Fibros
; 10(4): 228-33, 2011 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-21435954
9.
Miglustat effects on the basal nasal potential differences in cystic fibrosis.
J Cyst Fibros
; 12(1): 89, 2013 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-22727721
10.
Omalizumab for treatment of ABPA exacerbations in CF patients.
Pediatr Pulmonol
; 44(5): 516, 2009 May.
Artigo
Inglês
| MEDLINE | ID: mdl-19382216